Alphamab Oncology Doses First Patient in Phase III Cervical Cancer Trial of JSKN033

• Alphamab Oncology announced October 28, 2026, that the first patient received JSKN033 in a Phase III cervical cancer trial.
• The trial targets recurrent or metastatic disease following platinum-based chemotherapy and PD-1/PD-L1 inhibitor failure, regardless of HER2 or PD-L1 expression.
• The randomized study, JSKN033-301, compares JSKN033 monotherapy with physician-selected chemotherapy; primary endpoints are independently assessed progression-free survival and overall survival.
• JSKN033 is a subcutaneous co-formulation combining the HER2-targeted antibody-drug conjugate JSKN003 with the PD-L1 inhibitor envafolimab.
• Multiple Phase II studies are also underway, including first-line combination treatment for advanced cervical cancer and monotherapy for cervical and endometrial cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261028-12386577), on October 28, 2026, and is solely responsible for the information contained therein.